Global penny stocks show mixed performance, with some exhibiting strong earnings growth and profitability, while others face challenges like negative free cash flow and high leverage.
Trump administration unveils plans to lower U.S. drug prices through TrumpRx.com and 'Most Favored Nation' pricing strategy.
Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.
Global penny stocks show mixed performance, with some exhibiting strong earnings growth and profitability, while others face challenges like negative free cash flow and high leverage.
Trump administration unveils plans to lower U.S. drug prices through TrumpRx.com and 'Most Favored Nation' pricing strategy.
Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.